Evaluation of some biomarkers in breast cancer patients

Zakhary, Madeha M.; Mahmoud, Aida A.; Ahmed, Wael B.; Hashim, Marwa Shaaban

doi:10.21608/smj.2018.42078

Evaluation of some biomarkers in breast cancer patients

Document Type : Original Article

Authors

¹ Department OF Medical Biochemistry Faculty of Medicine. Assuit university.

² Department, of Medical Biochemistry, Faculty of Medicine, Sohag university.

³ Department, OF General Surgery, Faculty of Medicine, Sohag university.

⁴ Department of Biochemistry and microbiology, Facaulty of Medicine, Sohag University.

10.21608/smj.2018.42078

Abstract

Background. Osteopontin (OPN) is an extracellularmatrix protein that is overexpressed in various cancers and promotes onco-genic features including cell proliferation, survival, migration, and angiogenesis. Here, we analyzed the correlation between the expression pattern of (osteopontin and CA15.3) and clinic-pathological status of breast cancer and other standard prognostic factors.
Patients and methods. A case control study with 60 female breast cancer patients and 20 controls. All patients were subjected to complete medical history uptake , clinical examination and laboratory investigations include histopathological type of cancer, hormone receptor status ,CA 15-3 serum concentratios and osteopontin plasma level by ELISA.
Results. Our study showed that osteopontin plasma level was significantly different among breast cancers and controls (p<0.0001) but no association between osteopontin plasma level and histological type , stage or grade. Also we found significant association between CA 15-3 and cancer stage (p<0.000). Interestingly CA15.3 serum concentrations increased in hormone receptor positive cancer.
Conclusion. OPN and CA15.3 are overexpressed in breast cancer. OPN overexpression is associated with poor prognosis. Moreover CA15.3 has minimal prognostic value in non metastatic breast cancer.

References

1- Wang, C.-H., Li, J.-Z., & Zhang, W. (2014). "Breast cancer molecular subtypes of Uygur and Han in Xinjiang of China". International Journal of Clinical and Experimental Medicine, 7(4), 1116–1121.

2- Marques, R. C. B.; Costa-Rama, E. ;Viswanathan S. et al. (2018). "Voltammetric immunosensor for the simultaneous analysis of the breast cancer biomarkers CA 15-3 and HER2-ECD" J. Sensors and Actuators B: Chemical. Vol.255 no. 918-925.

3- Ahmed M and Kundu GC (2010). "osteopontin selectively regulates p70S6K/mTORphosphorylation leading to NF-κB dependentAP-1-mediated ICAM-1 expression in breast cancer cells " Molecular Cancer, 9:101.

4- Xu Y.Y., Zhang Y.Y., Lu W.F., Mi Y.J. and Chen Y.Q.. (2015)" Prognostic value of osteopontin expression in breast cancer: A meta-analysis" .Molecular and Clinical Oncology 3: 357-362.

5- Miller, E., Lee, H. J., Lulla, A., Hernandez, L., Gokare, P., & Lim, B. (2014). Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Research, 3, 198. http://doi.org/10.12688/f1000research.4340.1

6- Pacheco , J.G.; Silva, M.S.V.; Freitas, M. et al. (2018)." Molecularly imprinted electrochemical sensor for the point-of-care detection of a breast cancer biomarker (CA 15-3)"J. Sensors and Actuators B: Chemical. Vol. 256 no. 905-912.

7- THORAT, D., SAHU, A., BEHERA, R., et al. (2013). Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncology Letters, 6(6), 1559–1564.

8- GENG, B., LIANG, M.-M., YE, X.-B., & ZHAO, W.-Y. (2015). Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Molecular and Clinical Oncology, 3(1), 232–236.

9- Liu Y. , Lei H. , Zhang J. et al. (2015)" Associations between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis". PLoS ONE 10(8). : e0135318. doi:10.1371/journal.pone.0135318.

10- Bramwell V.H., Tuck A.B., Chapman J.-A.W. et al. (2014)"Assessment of osteopontin in early breast cancer:correlative study in a randomised clinical trial" . Breast Cancer Research , 16:R8

11- Brouckaert, O., Laenen, A., Wildiers, H. et al. (2013) "The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers" J. The Breast vol.22(3):254-262.

12- Li , H. , Chen k. ,Su F.et al. (2014). "Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer." Journal of Surgical Research 189(1): 48-56.